QRG Capital Management Inc. Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

QRG Capital Management Inc. lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 55.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,790 shares of the company’s stock after selling 20,037 shares during the period. QRG Capital Management Inc.’s holdings in Moderna were worth $1,055,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after buying an additional 5,129,800 shares in the last quarter. Capital World Investors lifted its stake in shares of Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after purchasing an additional 29,566 shares during the last quarter. National Pension Service grew its stake in Moderna by 10.3% during the 3rd quarter. National Pension Service now owns 813,893 shares of the company’s stock valued at $54,392,000 after purchasing an additional 75,817 shares in the last quarter. Finally, Matrix Capital Management Company LP increased its holdings in Moderna by 60.8% during the 1st quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock worth $77,789,000 after purchasing an additional 276,000 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on MRNA shares. Bank of America reduced their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. UBS Group decreased their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered their price objective on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $93.18.

Moderna Stock Down 6.9 %

MRNA stock opened at $46.83 on Friday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $61.85 and its 200 day simple moving average is $99.22. The stock has a market cap of $18.00 billion, a PE ratio of -3.04 and a beta of 1.69. Moderna, Inc. has a fifty-two week low of $46.57 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the company posted ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, sell-side analysts predict that Moderna, Inc. will post -9.89 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock valued at $238,531 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.